Investment site – 100 CSKD http://100cskd.com/ Thu, 02 Dec 2021 06:20:07 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://100cskd.com/wp-content/uploads/2021/06/cropped-icon-32x32.png Investment site – 100 CSKD http://100cskd.com/ 32 32 FUJIFILM Diosynth Biotechnologies Confirms £ 400 Million Investment Plans to Create UK’s Largest Multimodal Biopharmaceutical Manufacturing Site https://100cskd.com/fujifilm-diosynth-biotechnologies-confirms-400-million-investment-plans-to-create-uks-largest-multimodal-biopharmaceutical-manufacturing-site/ Thu, 02 Dec 2021 05:12:03 +0000 https://100cskd.com/fujifilm-diosynth-biotechnologies-confirms-400-million-investment-plans-to-create-uks-largest-multimodal-biopharmaceutical-manufacturing-site/

The expansion is expected to create up to 350 highly skilled jobs in Teesside.

BILLINGHAM, UK, December 02, 2021 (GLOBE NEWSWIRE) – FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, has confirmed a plan to £ 400million investment at its UK plant in Billingham, Teesside. This investment program more than doubles the site’s existing development and manufacturing footprint, creating the largest multimodal biopharmaceutical manufacturing site in the UK[1] and is expected to create up to 350 highly skilled jobs. The new facilities are expected to be operational by the end of 2023.

The new multimodal campus will include two new state-of-the-art facilities (a GMP viral gene therapy[2] and a GMP mammalian cell culture facility) and is part of a global 90 billion yen investment program initially defined by FUJIFILM Corporation in June 2021.

The investment will add a new cell culture facility at the expanded Billingham campus and triple the existing cell culture capacity capacities at the site with the addition of 4 x 2000 L and 2 single-use bioreactor production capacities. x 500 L for the manufacture of monoclonal and novel antibody treatments. This expansion will also include the addition of the company’s MaruX ™ GMP continuous manufacturing platform to provide customers with a differentiated, connected and integrated production platform offering.

In addition to the cell culture facility, the new investment program will expand the viral vector and gene therapy services offered by UK-based FUJIFILM Diosynth Biotechnologies with dedicated process development capabilities and a GMP gene therapy facility. viral on a commercial scale, both located on the Billingham Campus. This expansion will boost FUJIFILM Diosynth Biotechnologies’ gene therapy production capacities in the United Kingdom, thereby strengthening its leadership in the viral vector market; and complementing its existing global footprint, including sites in College Station, Texas and Watertown, Massachusetts, both in the United States. The investment will also facilitate the expansion of existing capacities in vaccine manufacturing, as well as new capacities, including mRNA production.

FUJIFILM Diosynth Biotechnologies previously announced plans to expand its viral vector and gene therapy offerings in Darlington, UK, with process development labs and manufacturing capabilities to support the production of experimental use of gene therapies in early stage clinical trials (first in humans). The process development labs have already started operations, with GMP manufacturing services starting in spring 2022.

In addition, an expansion of the existing 5,000 L GMP microbial production facilities will also take place at the Billingham campus. This expansion will increase the microbial fermentation capacity by almost two-thirds. The expansion will include more than 20,000 square feet of modular cleanroom space downstream, including two primary recovery and fallback suites, two purification suites and a column conditioning room. It is designed to implement SymphonX ™ from FUJIFILM Diosynth Biotechnologies[3] Technology. The expansion also includes quality control (QC) laboratories, offices and a materials warehouse. This extension will be operational at the end of 2023 / beginning of 2024.

“We all know there has never been a more important time to invest in biopharmaceuticals – and £ 400million, the biggest investment in UK biopharmaceutical manufacturing in decades, signal FUJIFILM’s intention Diosynth Biotechnologies to be able to offer multimodal options to meet the needs of our customers with flexibility and agility to help solve public health demands and deliver the drugs and vaccines of tomorrow ”, said Martin Meeson, CEO of FUJIFILM Diosynth Biotechnologies. “With a strong growing demand for microbial, cell culture and viral gene therapy services, we are adding the capacity and the latest technologies within a campus to deliver a range of modalities to create an offering that will provide promising new treatments for patients for years to come. “

“I am delighted that Fujifilm has identified the enormous potential for growth and innovation in the UK. At £ 400million, this is a significant investment in UK biopharmaceutical manufacturing and it will fuel our response to some of today’s most pressing global health challenges and deliver drugs and vaccines that change the lives of patients in need, ”said British Prime Minister Boris Johnson. “This will allow the expansion of the Billingham campus and create 350 new jobs – attracting top innovators and researchers and strengthening our life sciences industry as we rebuild better after the pandemic.” “

“Our vision is for the FUJIFILM Diosynth Biotechnologies site in Billingham to be the beating heart of the growing North East life science ecosystem, and this investment will create up to 350 highly skilled jobs and additional benefits in the local and national supply chain. Added Paul Found, COO, FUJIFILM Diosynth Biotechnologies UK.

## ENDS ##

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies is a leading contract biologics development and manufacturing (CDMO) organization with sites in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacture of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide range of microbial systems, mammals and host / virus. The company offers a comprehensive list of services ranging from cell line development using its proprietary pAVEway ™ and Apollo ™ X microbial cell line systems to process development, analytical development, clinical and commercial manufacturing approved by the Company. FDA. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, visit: www.fujifilmdiosynth.com.

About Fujifilm

FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting-edge solutions to a wide range of global industries by leveraging its in-depth knowledge and foundational technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its broad portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the fiscal year ended March 31, 2021, the company achieved worldwide revenue of $ 21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible stewardship of the environment and good corporate citizenship. For more information, please visit: https://www.fujifilmholdings.com.

[1] Based on internal company research in December 2021.

[2] Good Manufacturing Practices

[3] SymphonX is a unique downstream bioprocess hardware solution to support batch and continuous operations in biopharmaceutical manufacturing and increase efficiency through standardization of manufacturing operations.

CONTACT: Christine Jackman FUJIFILM Holdings America Corporation 9142614959 christine.jackman@fujifilm.com
Source link

]]>
Beneo invests millions to expand its chicory root fiber capacity https://100cskd.com/beneo-invests-millions-to-expand-its-chicory-root-fiber-capacity/ Tue, 30 Nov 2021 11:45:36 +0000 https://100cskd.com/beneo-invests-millions-to-expand-its-chicory-root-fiber-capacity/

With the start of work at both sites in early 2022, the program will ensure a capacity increase of over 40% in Beneo’s global chicory root fiber production to meet growing customer demand and drive market growth. .

This expansion stems from current market trends for digestive health, immunity, inner wellness, weight management, blood sugar management, and bone health, which have seen a high demand for root fiber. chicory prebiotics.

Over the past four years, the number of new product launches containing chicory root fiber inulin has increased by 50% globally (Euromonitor September 2021), with the market expected to reach USD 11.48 billion in 2028 (researchandmarkets.com).

Christoph Boettger, Member of the Management Board of Beneo, said: “Beneo’s chicory root fibers meet the key needs of today’s consumers and we are confident that they will continue to play a central role in healthy diets in the future. With increased capacity, Beneo continues to offer secure supply to its customers and partners around the world.

“In the summer of 2022, a second refinery line in Pemuco will already significantly increase production capacity. But we will not stop there. The recent investment decision will ensure the continued growth of Beneo’s production capacity. In addition to this increase in capacity, CO2 emissions are reduced. This means that the production site in Chile will be carbon neutral in a few years. In addition, the site in Belgium will have reduced specific energy consumption per tonne of product by more than 50% by 2030. ”